253 related articles for article (PubMed ID: 32696091)
1.
Roberts MJ; Morton A; Donato P; Kyle S; Pattison DA; Thomas P; Coughlin G; Esler R; Dunglison N; Gardiner RA; Doi SA; Emmett L; Yaxley J
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):477-482. PubMed ID: 32696091
[TBL] [Abstract][Full Text] [Related]
2. Improved specificity with
Donato P; Roberts MJ; Morton A; Kyle S; Coughlin G; Esler R; Dunglison N; Gardiner RA; Yaxley J
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):20-30. PubMed ID: 30229528
[TBL] [Abstract][Full Text] [Related]
3.
Nandurkar R; van Leeuwen P; Stricker P; Woo H; Kooner R; Yuen C; O'Neill G; Ende D; Cusick T; Ho B; Hickey A; Emmett L
Br J Radiol; 2019 Mar; 92(1095):20180667. PubMed ID: 30563350
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Can
Yin H; Chen M; Qiu X; Qiu L; Gao J; Li D; Fu Y; Huang H; Guo S; Zhang Q; Ai S; Wang F; Guo H
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3693-3701. PubMed ID: 33813594
[TBL] [Abstract][Full Text] [Related]
6. Gallium-68-prostate-specific membrane antigen (
van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
[TBL] [Abstract][Full Text] [Related]
7. Findings in 1,123 Men with Preoperative
Raveenthiran S; Yaxley WJ; Franklin T; Coughlin G; Roberts M; Gianduzzo T; Kua B; Samaratunga H; Delahunt B; Egevad L; Wong D; McEwan L; Brown N; Parkinson R; Esler R; Yaxley JW
J Urol; 2022 Mar; 207(3):573-580. PubMed ID: 34694140
[TBL] [Abstract][Full Text] [Related]
8.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
9. Increased Prostate Cancer Glucose Metabolism Detected by
Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
[TBL] [Abstract][Full Text] [Related]
10. Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer.
Bodar YJL; Veerman H; Meijer D; de Bie K; van Leeuwen PJ; Donswijk ML; van Moorselaar RJA; Hendrikse NH; Boellaard R; Oprea-Lager DE; Vis AN
BJU Int; 2022 Jun; 129(6):768-776. PubMed ID: 35166426
[TBL] [Abstract][Full Text] [Related]
11. Detection and localisation of primary prostate cancer using
Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M
BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
[TBL] [Abstract][Full Text] [Related]
12.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
13.
Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical Validation of PSMA Expression Measured by
Woythal N; Arsenic R; Kempkensteffen C; Miller K; Janssen JC; Huang K; Makowski MR; Brenner W; Prasad V
J Nucl Med; 2018 Feb; 59(2):238-243. PubMed ID: 28775203
[No Abstract] [Full Text] [Related]
15. Treatment Outcomes from
Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
[No Abstract] [Full Text] [Related]
16. Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy.
Roberts MJ; Morton A; Papa N; Franklin A; Raveenthiran S; Yaxley WJ; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Emmett L; Yaxley JW
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3289-3294. PubMed ID: 35298693
[TBL] [Abstract][Full Text] [Related]
17. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?
Demirci E; Kabasakal L; Şahin OE; Akgün E; Gültekin MH; Doğanca T; Tuna MB; Öbek C; Kiliç M; Esen T; Kural AR
Nucl Med Commun; 2019 Jan; 40(1):86-91. PubMed ID: 30395048
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with
Yaxley JW; Raveenthiran S; Nouhaud FX; Samartunga H; Yaxley AJ; Coughlin G; Delahunt B; Egevad L; McEwan L; Wong D
J Urol; 2019 Apr; 201(4):815-820. PubMed ID: 30672842
[TBL] [Abstract][Full Text] [Related]
19. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
Yilmaz B; Turkay R; Colakoglu Y; Baytekin HF; Ergul N; Sahin S; Tugcu V; Inci E; Tasci AI; Cermik TF
Prostate; 2019 Jun; 79(9):1007-1017. PubMed ID: 31012125
[TBL] [Abstract][Full Text] [Related]
20.
Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]